MEGACE
LOE ApproachingNDAORALTABLET
Approved
Aug 1971
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
MEGACE by Bristol Myers Squibb is cachexia. Approved for anorexia, cachexia, an unexplained significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids). First approved in 1971.
Drug data last refreshed 6d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MEGACE (megestrol acetate) is an oral small-molecule tablet approved in 1971 for treating anorexia, cachexia, and unexplained weight loss in AIDS patients. The precise mechanism by which megestrol acetate produces these effects remains unknown, though it is believed to act on appetite and metabolic pathways.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team downsizing and shift toward generic support or transition planning.
Worked on MEGACE at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.